

MPAC meeting 17 – 19 October 2017

Declaration of Interests

All MPAC members participating in the meeting updated and submitted their declaration of interest, which was assessed by the WHO Secretariat.

Nine members reported relevant conflict of interests, which are summarized below.

Thomas BURKOT

Received consulting and research support from Intellectual Ventures Labs (IVL) (support provided to the James Cook University) for two projects; one, as a consultant to supervise the evaluation of new malaria diagnostic test, which concluded in March 2017, and the other, as a secondment to develop a vector control strategy on mosquito proof housing and methods to age-grade mosquitos, which concluded in 2015. In 2015, Dr Burkot received research and non-monetary support from Vestergaard to evaluate and supervise the provision of Serofly insecticidal netting to evaluate impact on malaria in the Solomon Islands. From PATH, he provided consulting to support the grant application to DFID for attractive toxic sugar bait (ATSB) trials in Africa, which concluded in 2016. This interest was assessed to be non-personal, non-specific, and financially significant.*

Gabriel CARRASQUILLA

Directs ASIESALUD for consultancy and research in epidemiology and public health, where as technical adviser he has attended and supported the Latino American Dengue Advisory Board in 2015. As principal investigator, Dr Carrasquilla received two research grants from GSK; one to assess the impact of introduction of PVC in Colombia, and the other to assess the impact of introduction of Whooping Cough vaccine (Boostrix) in Bogotá, Colombia. Both contracts have been extended to the end of 2018. This interest was assessed as personal, non-specific and not financially significant.

Maureen COETZEE

Director of the Malaria Entomology Research Unit and DST/NRF Research Chair in Medical Entomology in the Faculty of Health Sciences, University of the Witwatersrand, Dr Coetzee's family member provided consulting for AngloGold/Ashanti carrying out mosquito surveys to inform vector control programmes on species present and susceptibility to four classes of insecticides. This contract ceased in April 2017. This interest was assessed as non-personal, non-specific and not financially significant.

Abdoulaye DJIMDÉ

Head of the malaria research at the Wellcome Trust Sanger Institute, Dr Djimdé works primarily on the genetic epidemiology of antimalarial drug resistance in West Africa. As technical adviser, he has been invited as invited speaker with honoraria for Novartis. This interest was assessed as personal, non-specific and not financially significant.

Azra GHANI

Professor in Infectious Disease Epidemiology at Imperial College London, currently, receives academic grant funding from multiple organisations: the Bill & Melinda Gates Foundation

(BMGF), IVCC, Malaria Vaccine Initiative (MVI), Medicines for Malaria Venture (MMV), Medical Research Council (MRC), Wellcome Trust, and the National Institutes of Health (NIH). At present, Professor Ghani is running a consultancy project for the Global Fund, which will end this year 2017. This interest was assessed to be non-personal, non-specific, and financially significant.*

Brian GREENWOOD

Manson Professor of Clinical Tropical Medicine at the London School of Hygiene and Tropical Medicine (LSHTM), he received a research grant from PATH for the LSHTM related to the evaluation of the RTS,S vaccines in Ghana, this project ceased in 2016. Currently, Professor Greenwood provides consultancy through the LSHTM to Johnson & Johnson on the development of long acting anti-malarial. This interest was assessed as non-personal, non-specific and financially significant*.

Caroline JONES

Senior Social Scientist on a joint global health trials grant funded by a partnership between the UK Department for International Development (DFID), MRC and the Wellcome Trust Global health Trials grant, which will provide evidence on whether improved housing can offer additional protection against clinical malaria over current best practice. Subsequently, receives a Wellcome Trust collaborative award on improving the efficacy of malaria prevention in an insecticide resistant Africa. Lastly, Dr Jones has been an invited speaker at the BMGF Eliminate Partners and Malaria Modelling Meeting held in London last year. The two partnerships will conclude in 2019. This interest was assessed as personal, specific and financially significant*.

Kevin MARSH

Chair of the MPAC at WHO and Senior Adviser for the African Academy of Sciences, he is on the malaria vaccines advisory group for USAID, member on the vaccines advisory group of PATH and on the malaria advisory group at the BMGF. Professor Marsh is a principal investigator on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine trial. This interest was assessed as non-personal, non-specific and not financially significant*.

8. Neena VALECHA

Directs the National Institute of Malaria Research (NIMR) in New Delhi, India, which receives research support to undertake the evaluation and its costs of pesticide products and trials of drugs and diagnostics of various companies, after obtaining approval from the Scientific Advisory Committee and the Ethical Committee. Please note Dr Valecha undersigns as the Head of the NIMR and research support is given to other scientists and investigators.

From WHO Pesticide Evaluation Scheme (WHOPES), several projects receive support; (1) on large scale (Phase III) evaluation of efficacy, fabric integrity and community acceptability of Permanent 3.0 long lasting insecticidal nets (LLINs), as well as (2) the evaluation of efficacy of LiferNet and Olyset Plus on LLINs. Subsequently, (3) on the evaluation of efficacy and residual activity of Fluodora® Fusion 562.5 WP-SB for indoor residual spraying. Receives support on (4) a field evaluation of combination long-lasting insecticidal net of

chlofenapyr and alpha-cypermethrin (interceptor G2® of BASE ®) and (5) financial support for GLP accreditation.

From MMW Geneva for Phase IIIB open label trial for safety and efficacy of Euratesim® in India against children with uncomplicated *pf*. This project was completed and ceased in July 2017, however there's an ongoing comprehensive case management in Odisha. This interest was assessed as non-personal, specific and not financially significant*.

Comments to further projects that have ceased.

*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding". Last update: 10th March 2016